Clinical Development RisksThere are risks such as delays in advancing preclinical candidates into clinical studies and unexpected safety issues, which could negatively impact the company's progress.
Financial PerformanceThe company reported a net loss of $0.42 per share, significantly higher than the forecasted net loss of $0.21 per share, due to higher-than-expected operating expenses.
Stock ValuationThe price target for the stock has been reduced from $10 to $5, due to dilution from financing and a slightly higher discount rate.